Share
COVID-19: Will a vaccine mean a return to normal life?
The race for a COVID-19 vaccine is getting tighter, with Moderna and Pfizer leading the way. Moderna announced that its candidate is 94.5 per cent effective, with Pfizer last week reporting 90 per cent efficacy for its candidate. These two have certainly raised the bar. Joining CNBC Africa for an analysis of the vaccine developments is Michael Breen, Director of Infectious Diseases and Ophthalmology at GlobalData.
Tue, 17 Nov 2020 16:34:19 GMT
SIGN UP FOR OUR NEWSLETTER
DAILY UPDATE
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.